Gilead Sciences Inc (GILD): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Gilead ( GILD) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.4%. By the end of trading, Gilead fell $0.69 (-1.1%) to $61.71 on average volume. Throughout the day, 6,477,242 shares of Gilead exchanged hands as compared to its average daily volume of 7,693,500 shares. The stock ranged in price between $61.37-$62.70 after having opened the day at $62.29 as compared to the previous trading day's close of $62.40. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 33.1%, Delcath Systems ( DCTH), down 11.9%, Zalicus ( ZLCS), down 11.7% and DARA Biosciences ( DARA), down 10.8%.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $96.0 billion and is part of the health care sector. Shares are up 70.8% year to date as of the close of trading on Wednesday. Currently there are 18 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the positive front, GW Pharmaceuticals PLC ADR ( GWPH), up 132.5%, Idera Pharmaceuticals ( IDRA), up 24.4%, Omeros Corporation ( OMER), up 18.2% and Oncolytics Biotech ( ONCY), up 16.8% , were all gainers within the drugs industry with GlaxoSmithKline ( GSK) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers